ISRG — Intuitive Surgical, Inc.

Price action is bearish: the Q2 2026 beat on July 21 was followed by selling, RSI is 42.19, and the stock sits below all major moving averages. Analysts still carry a Buy consensus with an average target near $491, but near-term market mood is dominated by procedure-normalization fears and high-multiple de-rating rather than by the strong operating results.

The three-year trend is clearly positive and inflecting higher on margins and cash flow. Revenue growth went from ~17% YoY in Q3 2024 to 19-23% through 2025; Q2 2026 grew 18.5% YoY, a modest deceleration from Q1 2026's 23% but still above 2024's pace. Operating margin expanded from ~25% in early 2024 to 33.6% in Q2 2026 (vs. 30.5% a year earlier), and GAAP EPS rose from $1.81 to $2.35 YoY. TTM free cash flow reached roughly $3.22B by June 2026, up over 60% from the year-earlier TTM period, driven by operating cash flow of $1.06B in Q2 2026 alone. This is not a cyclical-trough story; the business is at record profitability.

Expensive in absolute terms, cheap relative to its own history. TTM P/E is 41.5 and forward P/E is about 34 on next-FY EPS of $10.80; P/S is 11.75 and PEG is 1.95. Those compare with 5-year averages of 72.6x P/E and 19.3x P/S. At 34x forward earnings the market is paying a quality growth premium, but it is far below the multiples ISRG has commanded historically.

The stock is pricing in a growth/multiple scare rather than an earnings collapse. TTM EPS of $8.85 and next-FY estimates of $10.80 are well above current earnings, while the P/E has de-rated from the 5-year average of 72.6 to 41.5. In other words, earnings estimates are not falling; the multiple is shrinking. If procedure growth normalizes to mid-teens rather than falling to single digits, the current price already discounts a lot of bad news; if DV5 adoption reaccelerates, estimates could push the stock meaningfully higher from here.

Bearish trend, not yet oversold. As of 2026-08-27, RSI(14) was 42.19, below neutral but above the 30 oversold threshold. Price was 3.81% below the 20-day, 4.61% below the 50-day, and 21.83% below the 200-day, with the 52-week range at $328.57-$603.88. This is a downtrend; there is no confirmed bottom or momentum buy signal yet, and the low end of the range near $328 is the nearby support to watch.

• Interest-rate sensitivity: ISRG's high forward multiple makes it vulnerable to higher-for-longer rates; any shift toward rate cuts would be a tailwind for multiple expansion.
• GLP-1 narrative: concerns that weight-loss drugs could reduce bariatric/obesity-related procedures continue to cap sentiment, even though oncology/urology volumes are less exposed.
• Procedure growth normalization: post-pandemic catch-up demand has flattened; investors are watching for a glide path to a sustainable mid-teens growth rate.
• Healthcare policy and pricing: potential ACA tax-credit expiration, China pricing pressure, and international reimbursement/policy changes could weigh on international revenue.
• Hospital capital budgets: ~85% recurring revenue cushions the installed base, but new Da Vinci 5 placements and upgrades still depend on hospital spending cycles.

• Q3 2026 earnings (expected late October 2026): commentary on procedure-volume guidance and DV5 adoption trends will be the near-term catalyst.
• Da Vinci 5 upgrade cycle: pace of hospital conversions and 100+ planned software/hardware updates, plus regulatory and geographic clearances.
• Expansion of Ion and flexible robotic GI platforms in Europe and other direct-sales markets.
• A shift in interest-rate expectations could trigger a quick multiple re-rating.

• Continued multiple compression: the stock is already 21.8% below its 200-day; a further de-rating is possible if rates stay high or growth slows.
• Faster-than-expected procedure normalization or a material GLP-1 impact on surgical volumes.
• Da Vinci 5 conversion could take longer or be less margin-accretive than expected, or competition from Medtronic, J&J, and others could intensify.
• China/regulatory pricing actions or U.S. healthcare policy changes could pressure the international and capital-equipment portions of the model.

Intuitive Surgical is a structurally advantaged robotics franchise with 85% recurring revenue, no debt, 19% revenue growth, expanding margins, and record free cash flow. The 2026 de-rating to ~34x forward earnings is a reasonable entry point for long-term investors, but the near-term chart is weak and sentiment is bearish, so position sizing and patience matter. This is analysis, not personalized financial advice.

Theoretical fair value is $432, calculated by applying a 40x forward P/E to next-FY consensus EPS of $10.80. That multiple is well below ISRG's 5-year average P/E of 72.6 and modestly above the current 34x forward multiple, reflecting ~18-20% EPS growth, 67% gross margin, 31% operating margin, no debt, and the recurring-revenue moat, while still leaving a margin of safety versus the $491 analyst consensus.